受注:045-509-1970 |
技術サポート:[email protected] 平日9:00〜18:00 1営業日以内にご連絡を差し上げます |
Synonyms | BBI608 | Storage (From the date of receipt) |
3 years -20°C powder 1 years -80°C in solvent |
||||
化学式 | C14H8O4 |
||||||
分子量 | 240.21 | CAS No. | 83280-65-3 | ||||
Solubility (25°C)* | 体外 | DMSO | 12 mg/mL (49.95 mM) | ||||
Water | Insoluble | ||||||
Ethanol | Insoluble | ||||||
体内 (毎回新しく調製した物を用意してください) |
|
||||||
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
製品説明 | Napabucasin (BBI608) is an orally available Stat3 and cancer cell stemness inhibitor. |
---|---|
in vitro | Napabucasin downregulates stemness gene expression driven by Stat3 and cancer stemness properties, and effectively inhibits self-renewal of stemness-high cancer cells with IC50 ranged from 0.291~1.19 μM, on inhibition on normal stem cells. [1] |
in vivo | In mice bearing PaCa-2 xenografts, Napabucasin (20 mg/kg, i.p.) significantly inhibits tumor growth, relapse and metastasis. [1] |
細胞アッセイ | 細胞株 | Cancer stem cells U87-MG, U118, COLO205, DLD1, SW480, HCT116, FaDu, ACHN, SNU-475, Huh7, HepG2, H1975, A549, H460, CAOV-3, SW-626, PaCa2. |
---|---|---|
濃度 | ~2 μM | |
反応時間 | 72 h | |
実験の流れ | For cancer stem cells, spheres are dissociated and plated under cancer stem cell culture conditions on coated 96-well plates. After 72 h of culture, wells are dosed with the indicated compounds. Seventy-two hours or 24 h after dosing, CellTiter-Glo 2.0 is added to each well, and the luminescence is measured as described by the manufacturer. IC50 values are calculated by fitting a four parameter dose–response curve to normalized data using GraphPad Prism software. For bulk cells, cells are plated at 5,000 cells per well on 96-well plates. Twenty-four hours after plating, cells are treated with the indicated compounds. Viability is determined at 72 h as described above. |
|
動物実験 | 動物モデル | Mice bearing PaCa-2 xenografts |
投薬量 | 20 mg/kg | |
投与方法 | i.p. |
Serum amyloid A promotes glycolysis of neutrophils during PD-1 blockade resistance in hepatocellular carcinoma [ Nat Commun, 2024, 15(1):1754] | PubMed: 38409200 |
ADAR1-mediated RNA editing of SCD1 drives drug resistance and self-renewal in gastric cancer [ Nat Commun, 2023, 14(1):2861] | PubMed: 37208334 |
Targeting VCP potentiates immune checkpoint therapy for colorectal cancer [ Cell Rep, 2023, 42(11):113318] | PubMed: 37865914 |
Alcohol reshapes a liver premetastatic niche for cancer by extra- and intrahepatic crosstalk-mediated immune evasion [ Mol Ther, 2023, 31(9):2662-2680] | PubMed: 37469143 |
CRISPRi screens in human iPSC-derived astrocytes elucidate regulators of distinct inflammatory reactive states [ Nat Neurosci, 2022, 25(11):1528-1542] | PubMed: 36303069 |
Ligand-mediated PAI-1 inhibition in a mouse model of peritoneal carcinomatosis [ Cell Rep Med, 2022, 3(2):100526] | PubMed: 35243423 |
Targeted inhibition of STAT3 induces immunogenic cell death of hepatocellular carcinoma cells via glycolysis [ Mol Oncol, 2022, 16(15):2861-2880] | PubMed: 35665592 |
Identification of Novel Therapeutic Targets for Fibrolamellar Carcinoma Using Patient Derived Xenografts and Direct from Patient Screening [ Cancer Discov, 2021, candisc.0872.2020] | PubMed: 34127480 |
Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours [ Br J Cancer, 2021, 10.1038/s41416-021-01270-8] | PubMed: 33658640 |
Targeting EphA2 suppresses hepatocellular carcinoma initiation and progression by dual inhibition of JAK1/STAT3 and AKT signaling [ Cell Rep, 2021, 34(8):108765] | PubMed: 33626345 |
長期の保管のために-20°Cの下で製品を保ってください。
人間や獣医の診断であるか治療的な使用のためにでない。
各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。